Clinical Cancer Research · 2021 · 50 citations · 29 references
MedicineCancer BiologyOncologyImmunotherapyMolecular OncologyOncogenesCancer Cell SignalingCancer ImmunotherapyGene Fusions In CancerImmunotherapy For Breast CancerSignal Transduction In CancerCancer Cell Proliferation InhibitionCancer Cell Survival SignalingDriver Fusion GenesGene Fusion OncogenesisHumanized Xenograft ModelsOncogenic Fusion ProteinsTherapeutic Targeting Of Fusion ProteinsTumor Cell Survival Pathways
Abstract Purpose: Oncogenic fusions involving the neuregulin 1 (NRG1) gene are found in approximately 0.2% of cancers of diverse histologies. The resulting chimeric NRG1 proteins bind predominantly to HER3, leading to HER3-HER2 dimerization and activation of downstream growth and survival pathways. HER3 is, therefore, a rational target for therapy in NRG1 fusion–driven cancers. Experimental Design: We developed novel patient-derived and isogenic models of NRG1-rearranged cancers and examined the effect of the anti-HER3 antibody, seribantumab, on growth and activation of signaling networks in vitro and in vivo. Results: Seribantumab inhibited NRG1-stimulated growth of MCF-7 cells and growth of patient-derived breast (MDA-MB-175-VII, DOC4-NRG1 fusion) and lung (LUAD-0061AS3, SLC3A2-NRG1 fusion) cancer cells harboring NRG1 fusions or NRG1 amplification (HCC-95). In addition, seribantumab inhibited growth of isogenic HBEC cells expressing a CD74-NRG1 fusion (HBECp53-CD74-NRG1) and induced apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells. Induction of proapoptotic proteins and reduced expression of the cell-cycle regulator, cyclin D1, were observed in seribantumab-treated cells. Treatment of MDA-MB-175-VII, LUAD-0061AS3, and HBECp53-CD74-NRG1 cells with seribantumab reduced phosphorylation of EGFR, HER2, HER3, HER4, and known downstream signaling molecules, such as AKT and ERK1/2. Significantly, administration of seribantumab to mice bearing LUAD-0061AS3 patient-derived xenograft (PDX) and OV-10-0050 (ovarian cancer with CLU-NRG1 fusion) PDX tumors induced regression of tumors by 50%–100%. Afatinib was much less effective at blocking tumor growth. Conclusions: Seribantumab treatment blocked activation of the four ERBB family members and of downstream signaling, leading to inhibition of NRG1 fusion–dependent tumorigenesis in vitro and in vivo in breast, lung, and ovarian patient-derived cancer models.
29
A Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Herbert D. Soule, J. Vázquez, Anna Long et al. · JNCI Journal of the National Cancer Institute · 1973 · 2.5K citations
Medicine, Cell Biology, Oncology +10
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Fumihiko Ishikawa, Masaki Yasukawa, Bonnie Lyons et al. · Blood · 2005 · 920 citations · Full text
Life Sciences, Immunology, Pathology +15
<i>CD74–NRG1</i> Fusions in Lung Adenocarcinoma
Lynnette Fernandez‐Cuesta, Dennis Plenker, Hirotaka Osada et al. · Cancer Discovery · 2014 · 293 citations · Full text
The double dealing of cyclin D1
Cell Cycle · 2019 · 285 citations · Full text